Login to Your Account



Financings Roundup

Igenica to Advance mAb Platform with $33M Series C

By Marie Powers
Staff Writer

Wednesday, June 13, 2012
Privately held Igenica Inc. hooked Third Rock Ventures LLC, which traditionally launches biotech start-ups, as lead investor in a $33 million Series C to propel initial monoclonal antibody (mAb) candidates toward the clinic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription